Forma Therapeutics raises $25.5m to develop new cancer treatments

1 Dec 2009

Forma Therapeutics, a developer of a new generation of cancer therapies aimed at previously elusive, protein-protein drug targets, has closed on a $25.5m series B financing. The round was led by new investor Lilly Ventures, with participation from existing investors Novartis Option Fund and Bio*One Capital of Singapore.

Sorry, to read the full story you must be a Premium Subscriber

Are you a subscriber?

In order to view premium content you need to be a Premium Subscriber. You can subscribe now to access premium online content.

Become a Premium Subscriber
for only £150 / €180 / $225 p.a.

Login area

If you are already a AltAssets subscriber please log in below.

NEWS & VIEWS

Global private equity and venture capital news and research

By News Type

By PE Sector

By Region

By Region

Country Focus

PE Focus

Industry Focus

Other

AltAssets Events

Industry Events